Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder

Rebecca C Rossom, Stephanie A Hooker, Patrick J O'Connor, A Lauren Crain, JoAnn M Sperl-Hillen, Rebecca C Rossom, Stephanie A Hooker, Patrick J O'Connor, A Lauren Crain, JoAnn M Sperl-Hillen

Abstract

Background To compare estimated 10-year and 30-year cardiovascular risk in primary care patients with and without serious mental illness (SMI; bipolar disorder, schizophrenia, or schizoaffective disorder). Methods and Results All patients aged 18 to 75 years with a primary care visit in January 2016 to September 2018 were included and were grouped into those with and without SMI using diagnosis codes. Ten-year cardiovascular risk was estimated using atherosclerotic cardiovascular disease scores for patients aged 40 to 75 years without cardiovascular disease; 30-year cardiovascular risk was estimated using Framingham risk scores for patients aged 18 to 59 years without cardiovascular disease. Demographic, vital sign, medication, diagnosis, and health insurance data were collected from the electronic health record by a clinical decision support system. Descriptive statistics examined unadjusted differences, while general linear models examined differences for continuous variables and logistic regression models for categorical variables. Models were then adjusted for age, sex, race, ethnicity, and insurance type. A total of 11 333 patients with SMI and 579 924 patients without SMI were included. After covariate adjustment, 10-year cardiovascular risk was significantly higher in patients with SMI (mean, 9.44%; 95% CI, 9.29%-9.60%) compared with patients without SMI (mean, 7.99%; 95% CI, 7.97-8.02). Similarly, 30-year cardiovascular risk was significantly higher in those with SMI (25% of patients with SMI in the highest-risk group compared with 11% of patients without SMI; P<0.001). The individual cardiovascular risk factors contributing most to increased risk for those with SMI were elevated body mass index and smoking. Among SMI subtypes, patients with bipolar disorder had the highest 10-year cardiovascular risk, while patients with schizoaffective disorder had the highest 30-year cardiovascular risk. Conclusions The significantly increased cardiovascular risk associated with SMI is evident even in young adults. This suggests the importance of addressing uncontrolled major cardiovascular risk factors in those with SMI at as early an age as possible. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02451670.

Keywords: bipolar disorder; cardiovascular; risk factors; schizophrenia; serious mental illness.

Figures

Figure. Study participant flow.
Figure. Study participant flow.
EHR indicates electronic health record; and SMI, serious mental illness.

References

    1. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry. 2007;64:242–249. doi: 10.1001/archpsyc.64.2.242
    1. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta‐analysis. JAMA Psychiatry. 2015;72:334–341. doi: 10.1001/jamapsychiatry.2014.2502
    1. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, et al. A comparison of ten‐year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45–53. doi: 10.1016/j.schres.2005.08.010
    1. Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese schizophrenia spectrum patients have significantly higher 10‐year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics. 2013;54:67–73. doi: 10.1016/j.psym.2012.03.001
    1. Keenan TE, Yu A, Cooper LA, Appel LJ, Guallar E, Gennusa JV, Dickerson FB, Crum RM, Anderson CA, Campbell LM, et al. Racial patterns of cardiovascular disease risk factors in serious mental illness and the overall U.S. population. Schizophr Res. 2013;150:211–216. doi: 10.1016/j.schres.2013.07.022
    1. Goff DC, Lloyd‐Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–S73. doi: 10.1161/01.cir.0000437741.48606.98
    1. Rossom RC, O'Connor PJ, Crain AL, Waring S, Ohnsorg K, Taran A, Kopski K, Sperl‐Hillen JM. Pragmatic trial design of an intervention to reduce cardiovascular risk in people with serious mental illness. Contemp Clin Trials. 2020;91:105964. doi: 10.1016/j.cct.2020.105964
    1. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30‐year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078–3084. doi: 10.1161/circulationaha.108.816694
    1. Bibbins‐Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836–845. doi: 10.7326/m16-0577
    1. Hoang U, Goldacre MJ, Stewart R. Avoidable mortality in people with schizophrenia or bipolar disorder in England. Acta Psychiatr Scand. 2013;127:195–201. doi: 10.1111/acps.12045
    1. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753–760. doi: 10.1177/070674370404901106
    1. Garcia‐Portilla MP, Saiz PA, Bascaran MT, Martínez AS, Benabarre A, Sierra P, Torres P, Montes JM, Bousoño M, Bobes J. Cardiovascular risk in patients with bipolar disorder. J Affect Disord. 2009;115:302–308. doi: 10.1016/j.jad.2008.09.008
    1. Daumit GL, Dalcin AT, Dickerson FB, Miller ER, Evins AE, Cather C, Jerome GJ, Young DR, Charleston JB, Gennusa JV, et al. Effect of a comprehensive cardiovascular risk reduction intervention in persons with serious mental illness: a randomized clinical trial. JAMA Netw Open. 2020;3:e207247. doi: 10.1001/jamanetworkopen.2020.7247
    1. Corlin L, Short MI, Vasan RS, Xanthakis V. Association of the duration of ideal cardiovascular health through adulthood with cardiometabolic outcomes and mortality in the Framingham Offspring Study. JAMA Cardiol. 2020;5:549–556. doi: 10.1001/jamacardio.2020.0109
    1. Osborn DPJ, Hardoon S, Omar RZ, Holt RIG, King M, Larsen J, Marston L, Morris RW, Nazareth I, Walters K, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the Prediction and Management of Cardiovascular Risk in People With Severe Mental Illnesses (PRIMROSE) research program. JAMA Psychiatry. 2015;72:143–151. doi: 10.1001/jamapsychiatry.2014.2133
    1. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, Thapa‐Chhetri N, Fornaro M, Gallicchio D, Collantoni E, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–180. doi: 10.1002/wps.20420
    1. Gardner‐Sood P, Lally J, Smith S, Atakan Z, Ismail K, Greenwood KE, Keen A, O'Brien C, Onagbesan O, Fung C, et al. Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med. 2015;45:2619–2629. doi: 10.1017/s0033291715000562
    1. Correll CU, Druss BG, Lombardo I, O'Gorman C, Harnett JP, Sanders KN, Alvir JM, Cuffel BJ. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010;61:892–898. doi: 10.1176/ps.2010.61.9.892
    1. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24:412–424. doi: 10.1016/j.eurpsy.2009.01.005
    1. Pérez‐Piñar M, Mathur R, Foguet Q, Ayis S, Robson J, Ayerbe L. Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders. Eur Psychiatry. 2016;35:8–15. doi: 10.1016/j.eurpsy.2016.02.004
    1. Siskind DJ, Wu BT, Wong TT, Firth J, Kisely S. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta‐analysis, and network meta‐analysis. Lancet Psychiatry. 2020;7:762–774. doi: 10.1016/s2215-0366(20)30261-3
    1. Peckham E, Brabyn S, Cook L, Tew G, Gilbody S. Smoking cessation in severe mental ill health: what works? An updated systematic review and meta‐analysis. BMC Psychiatry. 2017;17:252. doi: 10.1186/s12888-017-1419-7
    1. Olsson E, Westman J, Sudic Hukic D, Eriksson SV, Edman G, Bodén R, Jedenius E, Reutfors J, Berntsson A, Hilding A, et al. Diabetes and glucose disturbances in patients with psychosis in Sweden. BMJ Open Diabetes Res Care. 2015;3:e000120. doi: 10.1136/bmjdrc-2015-000120
    1. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis. World Psychiatry. 2016;15:166–174. doi: 10.1002/wps.20309
    1. Ayerbe L, Forgnone I, Addo J, Siguero A, Gelati S, Ayis S. Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; a systematic review and meta‐analysis. J Affect Disord. 2018;225:665–670. doi: 10.1016/j.jad.2017.09.002
    1. Mitchell AJ, Lord O. Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. J Psychopharmacol. 2010;24:69–80. doi: 10.1177/1359786810382056
    1. Skrede S, Tvete IF, Tanum L, Steen VM, Bramness JG. Incident users of antipsychotic agents and future use of cholesterol‐lowering drugs: an observational, pharmacoepidemiologic study. J Clin Psychiatry. 2015;76:e111–e116. doi: 10.4088/JCP.14m08996
    1. Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Naess Ø, Ystrom E, Reichborn‐Kjennerud T, Hultman CM, Nesvåg R, Høye A. Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand. 2019;139:558–571. doi: 10.1111/acps.13017
    1. von Hausswolff‐Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl. 2009;119:15–21. doi: 10.1111/j.1600-0447.2008.01309.x
    1. Wang K, Gaitsch H, Poon H, Cox NJ, Rzhetsky A. Classification of common human diseases derived from shared genetic and environmental determinants. Nat Genet. 2017;49:1319–1325. doi: 10.1038/ng.3931
    1. Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016;10:193–202. doi: 10.1111/eip.12251

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren